<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45370">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02094326</url>
  </required_header>
  <id_info>
    <org_study_id>SAR-FAM-2013-01</org_study_id>
    <nct_id>NCT02094326</nct_id>
  </id_info>
  <brief_title>Study to Assess the Management of Synthetic Disease-modifying Antirheumatic Drug (DMARD) at the Onset of Adverse Events, Intolerance or Lack of Efficacy in Rheumatoid Arthritis (RA)</brief_title>
  <acronym>SAR FAME</acronym>
  <official_title>A Retrospective, Multicentre Observational Study to Assess the Management of Synthetic DMARD at the Onset of Adverse Events, Intolerance or Lack of Efficacy in Real Life in Patients With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Andaluza de Reumatología</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Andaluza de Reumatología</source>
  <oversight_info>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find patterns in the use of non-biological DMARDs as the
      initial treatment of RA and how adverse events (AEs), intolerance or lack of efficacy may
      impact therapeutic decisions in real life in the Spanish Andalusian region.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>Percentage of patients who present adverse events, intolerance or lack of efficacy to synthetic DMARDs that causes a change in treatment prescription when used in routine clinical practice</measure>
    <time_frame>6 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who present adverse events while on treatment with synthetic DMARDs and require a dose reduction of the synthetic DMARD in question</measure>
    <time_frame>6 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage of patients who experience adverse events while on treatment with synthetic DMARDs which forces drug withdrawal</measure>
    <time_frame>6 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage of patients who require an alternative DMARD due to lack of efficacy, defined as primary or secondary failure according to the rheumatologist in-charge of treatment</measure>
    <time_frame>6 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reasons for the different treatment strategies (discontinuation [temporary or permanent] versus dose reduction, failure due to lack of efficacy [primary or secondary] and the addition of other drugs) being adopted in the use of synthetic DMARDs.</measure>
    <time_frame>6 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>actual doses of the three first synthetic DMARDs used in clinical practice</measure>
    <time_frame>initiated treatment with at least one synthetic DMARD between January 2008 and December 2012</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage of patients who receive subcutaneous methotrexate and the reasons for receiving it (improved efficacy, reduced toxicity, other or unknown)</measure>
    <time_frame>6 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>exposure time of the first three synthetic DMARDs</measure>
    <time_frame>6 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with rheumatoid arthritis.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of both sexes ≥ 18 years.

          -  Patients diagnosed with RA (according to the American College of Rheumatology (ACR)
             2010 criteria) between January 2008 and December 2012 and who have initiated
             treatment with at least one synthetic DMARD during that period.

          -  Patients who have given written informed consent for their data to be collected and
             reviewed.

        Exclusion Criteria:

          -  Patients who are already participating in a clinical trial/s at the moment of
             participation in this study.

          -  Patients with whom it is suspected there will be insufficient information to complete
             the study objectives.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Federico Navarro, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Fundacion Andaluza de Reumatologia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Federico Navarro Sarabia, Dr.</last_name>
    <email>federico.navarro.sarabia@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Reina Sofía</name>
      <address>
        <city>Cordoba</city>
        <state>Andalucia</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerusalen Calvo, Dra.</last_name>
      <email>yeru83@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Jerusalen Calvo, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital San Cecilio</name>
      <address>
        <city>Granada</city>
        <state>Andalucia</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Sanchez, Dr.</last_name>
      <email>rsparera@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ricardo Sanchez, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <state>Andalucia</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfonso Gonzalez, Dr.</last_name>
      <email>agutrilla@wanadoo.es</email>
    </contact>
    <investigator>
      <last_name>Alfonso Gonzalez, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <state>Andalucia</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Garcia, Dr.</last_name>
      <email>angarcsan@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Antonio Garcia, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Carlos Haya</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inmaculada Ureña, Dra.</last_name>
      <email>med100082ster@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Inamculada Ureña, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Consulta Dra. Belmonte</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelines Belmonte, Dra.</last_name>
      <email>abelmontelopez@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Angelines Bemonte, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blanca Hernandez, Dra.</last_name>
      <email>blancahcruz@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Blanca Hernandez, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Consulta privada Dr. Rafael Cáliz</name>
      <address>
        <city>Granada</city>
        <state>Andalucía</state>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Caliz, Dr.</last_name>
      <email>rcalizcaliz@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Rafael Caliz, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Jaén</name>
      <address>
        <city>Jaén</city>
        <state>Andalucía</state>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Romero, Dr.</last_name>
      <email>aromero30@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Antonio Romero, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Xanit</name>
      <address>
        <city>Málaga</city>
        <state>Andalucía</state>
        <zip>29630</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginia Coret, Dra.</last_name>
      <email>vcoretc@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Virginia Coret, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>María del Carmen Romero, Dra.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Quirón Málaga</name>
      <address>
        <city>Málaga</city>
        <state>Andalucía</state>
        <zip>29004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Ordoñez, Dra.</last_name>
      <email>maricarmenoc@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Carmen Ordoñez, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana Nieto, Dra.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucía</state>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dolores Mendoza, Dra.</last_name>
      <email>dmendozamendoza@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Dolores Mendoza, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 24, 2014</lastchanged_date>
  <firstreceived_date>March 18, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antirheumatic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
